Biotechnology Company

Corcept Therapeutics

0%

Funding Goal
Funding Raised So Far $8,176,520
Funding Commitments $0
Funding Remaining
Funding Type Common Equity
Pre-Money Valuation
Investor Ownership
Interest / Dividend
Previous Funding

Company Overview


Corcept Therapeutics discovers and develops drugs that regulate the effects of cortisol. Since our founding in May 1998 we have been focused on the impact of cortisol and the potential benefits of developing glucocorticoid receptor antagonists.

About 80 percent of the tissues in the body have receptors for cortisol, and the effects of excess cortisol are severe and often life-threatening. Our initial research has been with mifepristone, which potently blocks the cortisol receptor.

On February 17, 2012, the FDA approved Korlym (mifepristone) in the United States as a once-daily oral medication for treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

Mifepristone is also being studied in a phase 3 trial, evaluating the impact of cortisol blockade on the psychotic features of psychotic depression. We plan to continue enrolling patients in this study throughout 2013.

lock icon

Invest in Company

Sign up or log in now to unlock profile details and access financials, company documents, and invest in companies.

Business Summary


Company Age
Employees
Sub-Industry
Prior Year Revenue
Current Year Revenue
Next Year Revenue

Management


Chief Executive Officer
David B......

Mr. is responsible for Maverick's Private Investments globally. He joined Maverick in 2004 from Oscient Pharmaceutical Corporation, where he was Chairman of the Board.

Mr. is a founder and former CEO of three healthcare companies: Affymetrix, Inc., Corcept Therapeutics, Inc., and Genesoft Pharmaceuticals, Oscient's predecessor. Mr. currently serves on the boards of several private companies.

Mr. received a B......A. from Yale University and an M.B......A. from Stanford University.

He was a Crown Fellow of the Aspen Institute, and is currently a Sterling Fellow of Yale University, a member of the Rand Corporation's Health Advisory Board and a director of College Track.

Chief Executive Officer
Joe B......

Patrick Enright
Director
Patrick E......

Patrick E...... is the Board Member at Esperion Therapeutics.
He has served as a Member Of Board Of Directors since April 2013.

He is also the Managing Director, Longitude Capital Management Co., LLC. Patrick is a founder of Longitude Capital Management Co., LLC, a venture capital firm focused on investments in biotechnology, and has served as its Managing Director since 2007.

From 2002 through 2006, Patrick was a Managing Director of Pequot Ventures where he co-led the life sciences investment practice.

Prior to Pequot, Patrick was a Managing Member responsible for the Delta Opportunity Fund, where he invested in privately held and publicly traded biotechnology companies.

Patrick is a director of a number of companies including,

Corcept Therapeutics, Inc. (NASDAQ: CORT),

Jazz Pharmaceuticals plc (NASDAQ: JAZZ).

Patrick earned an M.B.A. from the Wharton School of Business at the University of Pennsylvania.

B.S.

David Mahoney
Director
David M......

David M...... was appointed to Symantec's board of directors in April 2003. He previously served as co-CEO of McKesson HBOC, Inc. and as CEO of iMcKesson LLC from July 1999 to February 2001. M...... joined McKesson in 1990 as vice president for Strategic Planning, and was responsible for planning and corporate development.

He had overall responsibility for McKesson's strategic relations with pharmaceutical and biotechnology companies, was responsible for the establishment of the Pharmaceutical Partners Group at McKesson, and the launch of a new generics program.

Prior to joining McKesson, M...... was a principal with McKinsey & Company from 1981 to 1990. He serves on the board of directors of Adamas Pharmaceuticals, Corcept Therapeutics, Inc., Schwab Funds/Loudus Funds, SFMOMA, and Mercy Corps.

He has a bachelor's degree from Princeton University and a master's of business administration from Harvard University.

Joseph Turner
Director
Joseph T......

Joseph L. T...... has served as a member of our Board since January 2008. Mr. T...... retired from active employment in 2006 and currently serves on the board of directors of several companies.

From 1999 to 2006, Mr. T...... served as the Chief Financial Officer at Myogen, Inc., a pharmaceutical company, where he led several rounds of financing and was pivotal in the negotiation of the sale of the company.

Mr. T...... has also served in other finance roles including Director of Finance, Eli Lilly and Company, a biopharmaceutical company, (Switzerland) and Treasurer, Eli Lilly and Company (Switzerland).

He serves on the boards of four pharmaceutical companies: Alexza Pharmaceuticals, Inc., Corcept Therapeutics, Inc., BioClin Therapeutics, Inc. and Sophiris Bio Inc. Previously, he has served on the boards of NovaCardia, Inc., Sequel Pharmaceuticals, ApoLogic Inc., SGX Pharmaceuticals, Allos Therapeutics, Inc, and QLT Inc.

Mr. T...... received a B.A.

0%

Funding Goal
Funding Raised So Far $8,176,520
Funding Commitments $0
Funding Remaining
Funding Type Common Equity
Pre-Money Valuation
Investor Ownership
Interest / Dividend
Previous Funding

Documents


Contact


Corcept Therapeutics

Menlo Park, CA 94026, US

Top 10 Tips for Entrepreneurs Seeking Funding

Users who follow these tips increase their fundraising odds substantially.

  • Complete Your Funding Profile
    • Complete your funding profile with all sections filled, including your products and services, a complete management team with headshots, and slideshow with product images.
  • Complete a Business Plan (Optional)
    • Complete a Business Plan in EquityNet and refine your financial projections using the benchmarking alerts in the Business Plan Analysis report.
  • Upload Important Investment Documents
    • Upload and present any other important investment documents such as pitch decks, financial statements, and offering materials.
  • Use EquityNet Crowdcast
    • Use the EquityNet Crowdcast system to automatically email invitations to your contacts in order to build additional exposure for your company.
  • Construct Concise Introductory Messages
    • Construct and send a concise introductory message to investors, including primary reasons why they should want to invest such as KPIs, expected returns, and forecasted revenue.
  • Be Proactive in Messaging Investors
    • Be proactive in messaging many investors and include a simple way for them to connect with you for a web meeting or call, such as a Calendly link.
  • Use the Activity System
    • Use the Activity system to track interested investors, and send prompt follow-up messages to investors who viewed your profile or showed interest.
  • Prepare for Due Diligence
    • Prepare for due diligence questions by interested investors and use your Business Plan and investment documents to satisfy such requests.
  • Keep Your Funding Profile Updated
    • Keep your funding profile updated with new funding raised/committed and message interested investors with any new milestones achieved.
  • Do Not Respond to Unknown Investors
    • Do not respond to or engage any parties outside of EquityNet that are not listed as approved investors (this may happen due to your public profile and LinkedIn connections).